Masimo Shares Surge 34% Following $9.9 Billion Acquisition Deal by Danaher

Danaher Corporation has announced a definitive agreement to acquire Masimo, a leader in medical monitoring technologies, in an all-cash transaction valued at approximately $9.9 billion. Following the news, Masimo’s stock (MASI) surged by 34%, reflecting strong investor reaction to the offer of $180 per share in cash. This significant rally follows a period of prolonged stagnation for Masimo, whose stock had been underperforming with a -3% annual return prior to the deal. Upon completion, Masimo will operate as a standalone unit within Danaher’s diagnostics segment, integrating its high-growth medical solutions into Danaher’s global portfolio. The acquisition is designed to bolster Danaher’s leadership in the healthcare sector and drive long-term operational growth. Analysts view the move as a strategic positive that could lead to a re-rating of Danaher’s stock by incorporating high-value diagnostic assets.